Clinical and economic comparison of frovatriptan versus other oral triptans in the treatment of acute migraine in the real-world setting

Clinical Drug Investigation

Volumn 29, Issue 11, 2009, Pages 693-702

  Guidotti, Mario ^a   Ravasio, Roberto ^b  

^a VALDUCE HOSPITAL   (Italy)

^b Adis International Ltd   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SUMATRIPTAN; ZOLMITRIPTAN;

CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; MIGRAINE; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; SINGLE DRUG DOSE;

ACUTE DISEASE; ADMINISTRATION, ORAL; CARBAZOLES; DRUG COSTS; HUMANS; MIGRAINE DISORDERS; RECURRENCE; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 70350045266     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11315330-000000000-00000     Document Type: Review

References (34)

1. Lipton R, Stewart WF, Scher AI. Epidemiology and economic impact of migraine. Curr Med Res Opin 2001; 17 Suppl. 1: S4-12
2. Scher AI, Stewart WF, Lipton RB. Migraine and headache: a meta-analytic approach. In: Crombie IK, editor. Epidemiology of pain. Seattle (WA): IASP Press, 1999: 159-170
3. Steiner TJ, Scher AI, Stewart WF. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 2003; 23 (7): 519-527
4. Stovner LJ, Zwart JA, Hagen K. Epidemiology of headache in Europe. Eur J Neurol 2006; 13 (4): 333-345
5. Lanté ri-Minet M. Clinical use of triptans in the management of migraine. CNS Drugs 2006; 20 Suppl. 1: 12-23
6. Lipton R, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999; 39: 20-26
7. Goldstein J. Frovatriptan: a review. Expert Opin Pharmacother 2003 Jan; 4 (1): 83-93
8. Markus F, Mikko K. Frovatriptan review. Expert Opin Pharmacother 2007 Dec; 8 (17): 3029-3033
9. Balbisi EA. Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. Int J Clin Pract 2004 Jul; 58 (7): 695-705
10. Poolsup N, Leelasangaluk V, Jittangtrong J, et al. Efficacy and tolerability of frovatriptan in acute migraine treatment: treatment: systematic review of randomized controlled trials. J Clin Pharm Ther 2005 Dec; 30 (6): 521-532 (Pubitemid 43960978)
11. Hutchison J, Pfaffenrath V, Geraud G. A randomized, placebo-controlled, parallel-group trial of frovatriptan and sumatriptan for a single acute migraine attack [letter]. Eur J Neurol 2007; 14 Suppl. 1: 144
12. Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache 2002 Apr; 42 Suppl. 2: S93-9
13. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001 Nov 17; 358 (9294): 1668-1675
14. Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann Rheum Dis 1999 Nov; 58 Suppl. 1: i82-5
15. Lipton R, Hamelsky S, Kolodner K, et al. Migraine, quality of life, and depression: a population-based case-control study. Neurology 2000 Sep 12; 55 (5): 629-635
16. Terwindt GM, Ferrari MD, Tijhuis M, et al. The impact of migraine on quality of life in the general population: the GEM study. Neurology 2000 Sep 12; 55 (5): 624-629
17. Santanello NC, Davies G, Allen C, et al. Determinants of migraine-specific quality of life. Cephalalgia 2002 Oct; 22 (8): 680-685
18. Leonardi M. Migraine and disability: WHO's work to measure functioning, disability and health and the Global Burden of Diseases Study. J Headache Pain 2003; 4 Suppl. 1: s12-7
19. Visser WH, Jaspers NM, de Vriend RH, et al. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996 Jun; 16 (4): 264-269
20. Nicholson RA, Smith TR, Banks JW. Insurance limitations and cost of triptans negatively influence triptan use adherence and quality of life. Headache: J Head Face Pain 2007; 47 (5): 741-812
21. Folino-Gallo P, Palazzo F, Stirparo G, et al. Price differentials of oral triptans in eight European Union countries. J Headache Pain 2003; 4 (0): s67-9
22. Wallasch T-M. Frovatriptan in the practice of office-based neurologists and pain therapists: the ALADIN study. J Headache Pain. In press
23. Pfaffenrath V, Spierings ELH. Acute treatment of migraine attacks: frovatriptan 2.5mg an effective and economical alternative. Nervenheilkunde 2004; 23: 545-548
24. Leira R, Dualde E, del Barrio H, et al. Almotriptan versus rizatriptan in patients with migraine in Spain. Headache 2003 Jul-Aug; 43 (7): 734-741
25. Mathew NT, Kailasam J, Gentry P, et al. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache 2000 Jun; 40 (6): 464-465
26. Pascual J, Garcia-Monco C, Roig C, et al. Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: analysis of return to function and patient preference. Headache 2005 Oct; 45 (9): 1140-1150
27. Pascual J, Fite B, Lopez-Gil A. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. Headache 2002 Feb; 42 (2): 93-98
28. Massiou H, Pradalier A, Donnet A, et al. Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. TheMigraine - Satisfaction with Treatment: Reality with Almogran study. Eur Neurol 2006; 55 (4): 198-203
29. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002 Jan; 42 (1): 28-31
30. Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003 Apr; 43 (4): 376-388
31. Pascual J, Diener HC, Massiou H. Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example. J Headache Pain 2006 Feb; 7 (1): 27-33
32. Buchan P, Keywood C, Wade A, et al. Clinical pharmacokinetics of frovatriptan. Headache 2002 Apr; 42 Suppl. 2: S54-62
33. Kelman L, Von Seggern RL. Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy. Am J Ther 2006 Sep-Oct; 13 (5): 411-417
34. Ryan R, Geraud G, Goldstein J, et al. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache 2002 Apr; 42 Suppl. 2: S84-92